Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
77
Views
15
CrossRef citations to date
0
Altmetric
Original Research

The Nrf2/HO-1 axis can be a prognostic factor in clear cell renal cell carcinoma

Yu Deng1 Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Yong Wu2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;3 Department of Gynaecologic Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China
,
Ping Zhao4 Department of Pathology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, [email protected]
,
Weiwei Weng1 Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Min Ye1 Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Hui Sun1 Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Midie Xu1 Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
&
Chaofu Wang4 Department of Pathology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, [email protected]Correspondence[email protected]
 show all
Pages 1221-1230 | Published online: 07 Feb 2019

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yunning Huang, Yuanyuan Yang, Yuanyi Xu, Qian Ma, Fengying Guo, Yuan Zhao, Yuejia Tao, Mengqi Li & Jiaxin Guo. (2021) Nrf2/HO-1 Axis Regulates the Angiogenesis of Gastric Cancer via Targeting VEGF. Cancer Management and Research 13, pages 3155-3169.
Read now

Articles from other publishers (14)

Kenshiro Takemoto, Kohei Kobatake, Kento Miura, Takafumi Fukushima, Takashi Babasaki, Shunsuke Miyamoto, Yohei Sekino, Hiroyuki Kitano, Keisuke Goto, Kenichiro Ikeda, Keisuke Hieda, Tetsutaro Hayashi, Nobuyuki Hinata & Osamu Kaminuma. (2022) BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress‐related tumorigenicity . Cancer Science 114:2, pages 436-448.
Crossref
Youcef M. Rustum, Ryan Reis & Tara M. Rustum. (2023) Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy. International Journal of Molecular Sciences 24:2, pages 902.
Crossref
璇 周. (2023) Role of Nrf2/HO-1 Signaling Pathway in the Genesis and Treatment of Gastric Cancer. Advances in Clinical Medicine 13:04, pages 5536-5542.
Crossref
Liu MinnaMin BaiNa Cui, Yi DingPeng Zhang. (2022) Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma. annals of urologic oncology.
Crossref
Liam Baird, Thomas W. Kensler & Masayuki Yamamoto. (2022) Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality . IUBMB Life 74:12, pages 1209-1231.
Crossref
Ya Yang, Xin Wang, Jia Zhang, Hao Gu, Song Zhang, Hao Sun, Junqi Liu & Ruitai Fan. (2022) Abnormal phenotype of Nrf2 is associated with poor prognosis through hypoxic/VEGF-A-Rap1b/VEGFR2 pathway in gastric cancer. Aging 14:7, pages 3293-3312.
Crossref
Boda Chen, Dingchao Zhu, Chenglong Xie, Yifeng Shi, Libin Ni, Huawei Zhang, Sunlong Li, Jiajie Lu, Jian Xiao, Weiyi Xia, Chongan Huang & Xiangyang Wang. (2021) 18β-Glycyrrhetinic acid inhibits IL-1β-induced inflammatory response in mouse chondrocytes and prevents osteoarthritic progression by activating Nrf2. Food & Function 12:18, pages 8399-8410.
Crossref
Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang, Kent L. Nastiuk, John J. Krolewski & Xiang Ling. (2021) Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Emiliano PanieriLuciano Saso. (2021) Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells. Antioxidants & Redox Signaling 34:18, pages 1428-1483.
Crossref
Mariapaola Nitti, Caterina Ivaldo, Nicola Traverso & Anna Lisa Furfaro. (2021) Clinical Significance of Heme Oxygenase 1 in Tumor Progression. Antioxidants 10:5, pages 789.
Crossref
Sara Clerici & Alessandra Boletta. (2020) Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma. Cancers 12:11, pages 3458.
Crossref
Maira Di Tano, Franca Raucci, Claudio Vernieri, Irene Caffa, Roberta Buono, Maura Fanti, Sebastian Brandhorst, Giuseppe Curigliano, Alessio Nencioni, Filippo de Braud & Valter D. Longo. (2020) Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. Nature Communications 11:1.
Crossref
Yoshiyuki Yamaguchi, Takao Kamai, Satoru Higashi, Satoshi Murakami, Kyoko Arai, Hiromichi Shirataki & Ken-Ichiro Yoshida. (2019) Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer. BMC Cancer 19:1.
Crossref
Jing Zhang, Wanyin Cai, Zhixing Fan, Chaojun Yang, Wei Wang, Mengting Xiong, Cong Ma & Jian Yang. (2019) MicroRNA-24 inhibits the oxidative stress induced by vascular injury by activating the Nrf2/Ho-1 signaling pathway. Atherosclerosis 290, pages 9-18.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.